Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
10/2010
10/21/2010US20100267781 Naphthalene-based inhibitors of anti-apoptotic proteins
10/21/2010US20100267779 Novel Compounds and Methods of Using Them
10/21/2010US20100267777 Treatment of cancers with acquired resistance to kit inhibitors
10/21/2010US20100267763 Method of Decreasing Pro-ADAM10 Secretase and/or Beta Secretase Levels
10/21/2010US20100267759 INHIBITORS OF Akt ACTIVITY
10/21/2010US20100267754 Integrin expression inhibitor
10/21/2010US20100267753 Methods of treating disorders associated with protein kinase ck2 activity
10/21/2010US20100267752 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
10/21/2010US20100267748 HETEROCYCLIC COMPOUNDS USEFUL AS STEAROYL CoA DESATURASE INHIBITORS
10/21/2010US20100267742 Combination targeted therapy for lung cancer
10/21/2010US20100267732 Prognostic Molecular Markers for ET-743 Treatment
10/21/2010US20100267721 Heterocyclic H3 Antagonists
10/21/2010US20100267719 Enhanced Indolinone Based Protein Kinase Inhibitors
10/21/2010US20100267718 Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
10/21/2010US20100267715 Polymorph Form II of Tanaproget
10/21/2010US20100267711 Method of enhancing cellular production of molecular chaperone, hydroxylamine derivatives useful for enhancing the chaperone production and the preparation thereof
10/21/2010US20100267710 N3 alkylated benzimidazole derivatives as mek inhibitors
10/21/2010US20100267709 Inhibitors of janus kinases
10/21/2010US20100267707 Tyrosine Kinase Inhibitors
10/21/2010US20100267704 Autophagy Inducing Compounds and Uses Thereof in Treating Autophagy Associated Diseases
10/21/2010US20100267700 Immunosuppressive agent and anti-tumor agent comprising heterocyclic compound as active ingredient
10/21/2010US20100267699 Chemical compounds - 643
10/21/2010US20100267692 smac mimetic compounds as apoptosis inducers
10/21/2010US20100267689 4-azetidinyl-1-phenyl-cyclohexane antagonists of ccr2
10/21/2010US20100267688 4-azetidinyl-1-heteroaryl-cyclohexane antagonists of ccr2
10/21/2010US20100267683 Pharmaceutical composition comprising peroxided oil and cholesterol and uses thereof in medical field
10/21/2010US20100267681 Fat or oil composition
10/21/2010US20100267675 Compositions Comprising Sphingosine 1 Phosphate (S1P) Receptor Modulators
10/21/2010US20100267674 Calcium/sodium salt of inositol tripyrophosphate as an allosteric effector of hemoglobin
10/21/2010US20100267673 Protein phosphatase 2a-activating agents
10/21/2010US20100267672 Novel compounds of reverse-turn mimetics, method for manufacturing the same and use thereof
10/21/2010US20100267671 Compositions and methods for apoptosis modulators
10/21/2010US20100267668 4-azetidinyl-1-heteroatom linked-cyclohexane antagonists of ccr2
10/21/2010US20100267667 Telomerase activating compounds and methods of use thereof
10/21/2010US20100267666 Pyrrolopyrazine kinase inhibitors
10/21/2010US20100267663 A composition for cicatrisation processes in the treatment of hypertrophic scars and for improving the biomechanical properties of the cutis
10/21/2010US20100267661 Beta glucans and methods of use thereof
10/21/2010US20100267657 Antimetabolite agent combinations in the treatment of cancer
10/21/2010US20100267656 Myeloid differentiation inducing agents
10/21/2010US20100267655 Glycosylated Warfarin Analogs and Uses Thereof
10/21/2010US20100267652 Method of inhibiting abcg2 and related treatments
10/21/2010US20100267648 Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides
10/21/2010US20100267644 Cystatin C as an Antagonist of TGF-BETA and Methods Related Thereto
10/21/2010US20100267637 Treatment of melanoma with alpha thymosin peptides in combination with a kinase inhibitor
10/21/2010US20100267633 N-(4-Oxo-3,4-Dihydroquinazolin-2Yl) Butanamides as Androgen Receptor Modulators
10/21/2010US20100267626 Methods and compositions for measuring wnt activation and for treating wnt-related cancers
10/21/2010US20100267623 Peptides with capacity to bind to scurfin and applications
10/21/2010US20100267621 Antimicrobial Compounds and Formulations
10/21/2010US20100267620 Methods for slowing senescence and treating and preventing diseases associated with senescence
10/21/2010US20100267615 Methods for treatment and/or prevention of a disease associated with vascular leak
10/21/2010US20100267608 Modifications of cupredoxin derived peptides and methods of use thereof
10/21/2010US20100267140 Soluble inhibitors of vascular endothelial growth factor and use thereof
10/21/2010US20100267045 Cudr as biomarker for cancer progression and therapeutic response
10/21/2010US20100267027 Her-2 binding antagonists
10/21/2010US20100266707 Method of treating cachexia with the removal or inactivation of macrophage inhibitory cytokine-1
10/21/2010US20100266706 Oral particulate antitumor preparation
10/21/2010US20100266705 Nanoparticulate megestrol formulations
10/21/2010US20100266695 Multivalent clustering targeting strategy for drug carriers
10/21/2010US20100266680 Treatment of Cancer Using TLR3 Agonists
10/21/2010US20100266679 Crystalline modifications of n-alpha-(2,4,6-triisopropylphenylsulfonyl)-3-hydroxyamidino- (l)- phenylalanine 4-ethoxycarbonylpiperazide and/or salts thereof
10/21/2010US20100266675 Lipoproteins, lipopeptides and analogs, and methods for making and using them
10/21/2010US20100266674 L-oddc prodrugs for cancer
10/21/2010US20100266668 Manufacturing Dissolvable Dosage Forms
10/21/2010US20100266644 Methods and compositions for administration of iron
10/21/2010US20100266642 Modified cells for targeted cell trafficking and uses thereof
10/21/2010US20100266621 Methods and systems for treating cell proliferation disorders with psoralen derivatives
10/21/2010US20100266618 Compositions and methods for augmenting activity of oncolytic viruses
10/21/2010US20100266617 Antibodies to human programmed death receptor pd-1
10/21/2010US20100266616 Polypeptides, antibody variable domains and antagonists
10/21/2010US20100266608 treating a solid malignant proliferative disease or hematological proliferative disease by using inhibitor to human IL-17
10/21/2010US20100266604 Use of tam receptor inhibitors as immunoenhancers and tam activators as immunosuppressors
10/21/2010US20100266601 Antibodies that inhibit tslp activity
10/21/2010US20100266599 Human receptor proteins; related reagents and methods
10/21/2010US20100266597 Cytokine receptor zcytor17 multimers
10/21/2010US20100266593 Wnt antagonists and their use in the diagnosis and treatment of wnt-mediated disorders
10/21/2010US20100266592 Therapeutic antennapedia-antibody molecules and methods of use thereof
10/21/2010US20100266590 Combination therapy
10/21/2010US20100266589 Adjuvant cancer therapy
10/21/2010US20100266588 Breast Cancer Susceptibility Gene GT198 and Uses Thereof
10/21/2010US20100266587 Compositions and Methods to Treat Acute Myelogenous Leukemia
10/21/2010US20100266581 Compositions and methods for modulating s-nitrosogluthione reductase
10/21/2010US20100266577 Method of Cancer Treatment with Antagonists of FAS Inhibitors
10/21/2010US20100266570 Dimeric derivatives of artemisinin and application in anticancer therapy
10/21/2010US20100266565 Combinational Chemotherapy Treatment
10/21/2010US20100266556 Method for expanding hematopoietic stem cells using heterocyclic compound
10/21/2010US20100266550 Mammalian milk microorganisms, compositions containing them and their use for the treatment of mastitis
10/21/2010US20100266548 LPS-Responsive CHS1/Beige-Like Anchor Gene and Therapeutic Applications Thereof
10/21/2010US20100266547 Methods and compositions for treatment of interferon-resistant tumors
10/21/2010US20100266546 Selectively replicating viral vectors
10/21/2010US20100266542 Receptor coupling agents and therapeutic uses thereof
10/21/2010US20100266540 Drug class for the treatment of cancer
10/21/2010US20100266539 Chemokine receptor antagonist and medical use thereof
10/21/2010US20100266538 Quinoxaline derivatives and their use for treating benign and malignant tumour disorders
10/21/2010US20100266535 Compounds Having CRTH2 Antagonist Activity
10/21/2010US20100266533 Death Domain Containing Receptors
10/21/2010US20100266531 Il-17 binding proteins
10/21/2010US20100266527 Anti-microbial polymers and their compositions
10/21/2010US20100266510 Foamable Vehicle and Pharmaceutical Compositions Thereof
10/21/2010US20100266502 Pharmaceutical composition comprising anti-HB-EGF antibody as active ingredient
10/21/2010US20100266498 Nucleic acid and corresponding protein entitled 125p5c8 useful in treatment and detection of cancer
1 ... 622 623 624 625 626 627 628 629 630 631 632 633 634 635 636 637 638 639 640 641 642 ... 2211